Controlled drags prescribers

The main drawback of RP is that cost containment is not always achieved, and when it is, it is fleeting. The reasons for the limited effect (small, shortterm savings) of RP on cost containment are (a) as we have seen, it is applied to a limited proportion of the market, which is generally not that which leads the growth in expenditure, (b) companies react by recovering the losses incurred on the products covered by the system through price increases in non-covered products, and (c) the system seeks to control prices yet does not influence either the increase in the number of drags prescribed or the structure of this consumption. 

Reisch, M. Drag Price Controls Manufacturers Prescribe Self-Regulation, Chem. Eng. Neyvs, 71(12), 6 (1992). 

Co-payment is an instrument that should not be used on its own. Neither efficiency in drag use nor equity nor the control of pharmaceutical expenditure can rest solely on co-payment. Its effectiveness is reinforced when it is combined with other instruments and incentives. In fact, all European countries combine, in different doses and proportions, multiple instruments that influence the behaviour of the industry, prescribes and patients. It is sufficient to recall that pharmaceutical expenditure is the product of price by quantity, and to consider the enormous international variability of drag prices,35 in order to understand the limitations of co-payment regulation in comparison with other policies that influence prices. Policies aimed at price control can be as effective as co-payment - or more so - for purposes of cost containment. 

Barbiturates produce forms of central nervous system depression. Reactions to these drags range from mild sedation (producing sleep) to a coma. Doctors may prescribe barbiturates as sedatives to calm patients nerves, reduce tension or help them sleep. The drugs are also used as an anticonvulsant to control epileptic seizures. 

Midha K, Rawson M, Hubbard J. Prescribability and switchability of highly variable drags. J Control Release 1999 62 33-40. 

In stark contrast with most other pharmacologic delivery methods (e.g., pills, intravenous), there is little control on what amount of drug is actually delivered to the target tissue (i.e., the ocular surface) when a physician prescribes a topical formulation. To overcome this problan, investigators have attempted to deliver medications by spraying the drug onto the eye, but initial efforts with such systems as atomizer sprays have failed due to the inability to control droplet size and flow dynamics for consistent and predictable administration. Major problans related to the physics of droplet ejection, such as dispersion, droplet evaporation, drag, and non-coUimated flow turbulence, have held back such new approaches until recently. ... 

---